Active Biotech’s Tasquinimod Shows Promise in Multiple Myeloma Study

An update from Active Biotech AB ( (SE:ACTI) ) is now available.

Active Biotech AB announced promising study results for tasquinimod, an immunomodulatory treatment, in combination with standard therapies for patients with relapsed refractory multiple myeloma. The study showed that tasquinimod is well-tolerated and exhibits anti-myeloma activity, even in patients who have previously been refractory to standard treatments. These findings suggest that tasquinimod could enhance the efficacy of existing myeloma therapies, potentially improving treatment outcomes for heavily pre-treated patients.

More about Active Biotech AB

Active Biotech AB is a biotechnology company focused on developing first-in-class immunomodulatory treatments for oncology and immunology indications with high unmet medical needs. The company has a portfolio of projects, including tasquinimod and laquinimod, which are small molecule immunomodulators targeting hematological malignancies and inflammatory eye disorders. Active Biotech is also involved in developing naptumomab, a targeted anti-cancer immunotherapy.

Average Trading Volume: 13,676,599

Current Market Cap: SEK192.6M

Find detailed analytics on ACTI stock on TipRanks’ Stock Analysis page.